TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
10x Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$69.89+0.03 (+0.04%)
Close on Oct 19, 2026
- Market cap
- $9.08B
- P/E (TTM)
- –
- Dividend yield
- –
10x Genomics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products and services revenue | $149.09M | $149.90M | $165.69M | $148.02M | $145.16M | $137.82M | $164.91M | $151.56M | $152.99M | $141.01M | – | – | 98.7% | +2.7% |
| Consumables | $130.75M | $129.80M | $141.75M | $127.89M | $122.19M | $115.36M | $133.53M | $126.20M | $123.36M | $110.34M | $140.31M | $114.37M | 86.6% | +7.0% |
| Single Cell | $88.45M | $88.89M | – | $92.52M | $85.79M | $84.11M | $97.74M | $96.54M | $94.11M | $83.93M | $118.14M | $100.28M | 58.6% | +3.1% |
| Spatial | $42.30M | $40.91M | $40.96M | $35.37M | $36.40M | $31.25M | $35.79M | $29.67M | $29.25M | $26.41M | $22.17M | $14.09M | 28.0% | +16.2% |
| Services | $10.68M | $8.83M | $8.47M | $8.13M | $8.48M | $7.65M | $7.03M | $6.30M | $5.78M | $5.22M | $5.27M | $4.33M | 7.1% | +26.0% |
| Instruments | $7.66M | $11.26M | $15.47M | $12.00M | $14.50M | $14.82M | $24.35M | $19.06M | $23.85M | $25.45M | $38.40M | $34.94M | 5.1% | -47.2% |
| Spatial | $4.57M | $6.04M | $9.36M | $7.07M | $8.77M | $8.90M | $13.43M | $11.42M | $15.06M | $17.60M | $27.25M | $22.71M | 3.0% | -47.8% |
| Single Cell | $3.09M | $5.22M | – | $4.93M | $5.73M | $5.91M | $10.93M | $7.64M | $8.79M | $7.85M | $11.15M | $12.23M | 2.0% | -46.1% |
| License and royalty revenue | $1.94M | $947.00K | $341.00K | $983.00K | $27.75M | $17.06M | $111.00K | $95.00K | $114.00K | $1.00K | – | – | 1.3% | -93.0% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $85.03M | $80.10M | $82.17M | $79.87M | $106.16M | $90.57M | $87.22M | $87.82M | $93.09M | $79.63M | $103.84M | $99.01M | 56.3% | -19.9% |
| United States | $82.11M | $76.69M | $78.96M | $77.25M | $103.49M | $86.82M | $84.29M | $84.72M | $89.67M | $75.64M | $99.32M | $96.09M | 54.4% | -20.7% |
| Europe, Middle East and Africa | $39.97M | $36.85M | $53.46M | $41.62M | $34.73M | $31.90M | $49.83M | $37.85M | $37.36M | $34.72M | $50.59M | $32.02M | 26.5% | +15.1% |
| Asia-Pacific | $26.04M | $33.89M | $30.39M | $27.51M | $32.02M | $32.42M | $27.97M | $25.98M | $22.65M | $26.66M | $29.55M | $22.61M | 17.2% | -18.7% |
| China | $14.97M | $15.84M | $15.02M | $15.19M | $23.17M | $16.88M | $14.61M | $15.03M | $13.74M | $13.92M | $11.75M | $12.43M | 9.9% | -35.4% |
| Asia-Pacific (excluding China) | $11.07M | $18.06M | $15.37M | $12.32M | $8.85M | $15.54M | $13.36M | $10.95M | $8.91M | $12.73M | $17.80M | $10.18M | 7.3% | +25.1% |
| Americas (excluding United States) | $2.92M | $3.41M | $3.22M | $2.63M | $2.67M | $3.75M | $2.94M | $3.10M | $3.42M | $3.99M | $4.52M | $2.92M | 1.9% | +9.4% |
From the segment and revenue-disaggregation notes of 10x Genomics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.